# Unicycive Therapeutics (UNCY) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/UNCY
## Company Profile
- Ticker: UNCY
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 3.73 USD
- Market cap: 193041195.21 USD
- Last updated: 2026-10-13
## Business Overview
### Kidney Disease Therapeutics
Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.
### Oxylanthanum Carbonate
Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients. It is designed to achieve phosphate control with a lower pill burden than commonly used therapies.
### Regulatory Resubmission Path
The FDA's prior review did not identify efficacy or safety deficiencies but required resolution of manufacturing-facility issues. A third-party vendor inspection is the key step preceding NDA resubmission.
## Why The Stock Is Moving

As of Oct 13, 2026, UNCY closed down 7.90% at $3.73. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of the FDA inspection of the third-party oxylanthanum carbonate manufacturing facility.
- Resubmission of the oxylanthanum carbonate NDA following a successful facility inspection.

## Recent News
- 2026-10-01 11:05 EST — [Unicycive Therapeutics Appoints Meredith Manning to Board of Directors](https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-appoints-meredith-manning-to-board-of-directors-9cd4a932) — Source: Unicycive Therapeutics
- 2026-09-29 11:05 EST — [Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate](https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-announces-resubmission-of-new-drug-application-for-oxylan-72f41c48) — Source: Unicycive Therapeutics
- 2026-09-01 11:05 EST — [Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-to-present-at-the-h-c-wainwright-28th-annual-global-inves-625af9dc) — Source: Unicycive Therapeutics
- 2026-08-12 11:19 EST — [Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-announces-second-quarter-2026-financial-results-and-provi-adb5adad) — Source: Unicycive Therapeutics
- 2026-06-30 11:05 EST — [Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)](https://biopharmsignal.com/news/UNCY/unicycive-therapeutics-receives-complete-response-letter-from-fda-regarding-resu-2c152ab0) — Source: Unicycive Therapeutics